Key Insights

Highlights

Success Rate

86% trial completion

Published Results

23 trials with published results (13%)

Research Maturity

92 completed trials (52% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 52/100

Termination Rate

8.5%

15 terminated out of 177 trials

Success Rate

86.0%

-0.6% vs benchmark

Late-Stage Pipeline

13%

23 trials in Phase 3/4

Results Transparency

25%

23 of 92 completed with results

Key Signals

23 with results86% success15 terminated

Data Visualizations

Phase Distribution

122Total
Not Applicable (61)
Early P 1 (4)
P 1 (12)
P 2 (22)
P 3 (8)
P 4 (15)

Trial Status

Completed92
Unknown33
Recruiting19
Terminated15
Not Yet Recruiting8
Withdrawn5

Trial Success Rate

86.0%

Benchmark: 86.5%

Based on 92 completed trials

Clinical Trials (177)

Showing 20 of 20 trials
NCT07737340Recruiting

Metabolic Liver Disease in Newly Diagnosed People Living With HIV (MASHIV-TR)

NCT02520609Completed

Dynamic Post-Prandial Metabolism in Patients With Non-Alcoholic Fatty Liver Disease

NCT00862433Phase 1Completed

Vitamin E Pharmacokinetics and Biomarkers in Normal and Obese Women

NCT04302051Withdrawn

Assessment of Fatty Liver With Thermo-acoustic Device

NCT03481829Recruiting

Early Tracking of Childhood Health Determinants (ETCHED) Study

NCT03849235Not ApplicableCompleted

A Pathophysiological Study of the Postprandial Human Liver (PLS)

NCT05804422Not ApplicableCompleted

Probiotic Lysate (Postbiotic and Metabiotic) Supplementation for Adults NAFLD Patients (DELI_NAFLD Study)

NCT07646197Not ApplicableRecruiting

Effects of Peanut Consumption on Adults With Metabolic Associated Fatty Liver Disease

NCT07636915Not Yet RecruitingPrimary

Association Between Fatty Liver and Inflammatory Biomarkers

NCT06225193RecruitingPrimary

Exploratory Analysis of Enhanced Liver Function (ELF) Test to Detect Early Fatty Liver in High Risk Population

NCT05370053Not ApplicableCompletedPrimary

The Availability of the Enhanced Liver Fibrosis (ELF) Test Affects the Rate of Diagnosis of Nonalcoholic Steatohepatitis (NASH) With Fibrosis in Patients Referred to Hepatology

NCT07564947Not ApplicableEnrolling By Invitation

Impact of Ganoderma Lucidum on NRF2 Levels and Antioxidant Status in Metabolic Asscociated Fatty Liver Disease (GL-MAFLD-NRF2 Study)

NCT07530419Not Yet Recruiting

Samsung S-Viscosity vs Canon Dispersion Slope in Steatotic Liver Disease (SAVID-SLD)

NCT07495332Not ApplicableRecruitingPrimary

Siemens Biomarker Multi-modality

NCT07449767Not ApplicableCompleted

Effects of Short-Term Resistance Training on Diaphragm Thickness, Hepatic Fat Density, and Quality of Life in Healthy Older Men

NCT06546384Not ApplicableNot Yet Recruiting

GLP-1 RA on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease

NCT07399600Not ApplicableNot Yet Recruiting

Personalized Transcranial Magnetic Stimulation (TMS) for Metabolic Dysfunction and Alcohol-Related Liver Disease

NCT07362745CompletedPrimary

Single-Cell and Spatial Transcriptomics Analysis of Steatotic Donor Liver Susceptibility to Post-Transplant Injury

NCT04899102Not ApplicableRecruitingPrimary

Intermittent Fasting for NAFLD in Adults

NCT07242222Phase 1RecruitingPrimary

Erdosteine in the Treatment of Nonalcoholic Fatty Liver Disease

Scroll to load more

Research Network

Activity Timeline